The market for influenza vaccines in the United States will at some point rebound, one of the manufacturers of the shot predicted on Nov. 4.
“When you overlay the hospitalization trends, what you see is a clear correlation between the reduced immunization rates and the higher disease burden,” Dave Ross, senior vice president and general manager of CSL Seqirus, told investors.
“This past flu season represented the worst influenza season in the past 15 years. So what we know is that disease is rising while immunization rates are declining. What we don’t know yet is when that rising burden of disease will trigger the change in behavior that’s needed to see immunization rates recover. In the end, we feel very strongly that science and data will prevail and the public health consequences will ultimately be too big to ignore,” he added….